Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;19(2):93-94.
doi: 10.1038/s41575-021-00569-4.

Optimizing immunotherapy for colorectal cancer

Karuna Ganesh  1
Affiliations
Review

Optimizing immunotherapy for colorectal cancer

Karuna Ganesh. Nat Rev Gastroenterol Hepatol. 2022 Feb.

Abstract

Important colorectal cancer (CRC) studies in 2021, including a new standard of care for first-line treatment of MSI-H–dMMR metastatic CRC, single-cell and spatial analysis of primary tumours and investigations of diet in preclinical models of cancer initiation, have provided novel insights into the CRC immune microenvironment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The author declares no competing interests.

Figures

Figure 1.
Figure 1.
Modulating the local and systemic immune microenvironment of colorectal cancer. Three studies, , have advanced our understanding of colorectal cancer immune microenvironment.
See this image and copyright information in PMC

References

    1. Ganesh K et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 16, 361–375, doi:10.1038/s41575-019-0126-x (2019). - DOI - PMC - PubMed
    1. Le DT et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372, 2509–2520, doi:10.1056/NEJMoa1500596 (2015). - DOI - PMC - PubMed
    1. Overman MJ et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18, 1182–1191, doi:10.1016/S1470-2045(17)30422-9 (2017). - DOI - PMC - PubMed
    1. Andre T et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 383, 2207–2218, doi:10.1056/NEJMoa2017699 (2020). - DOI - PubMed
    1. Overman MJ et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 36, 773–779, doi:10.1200/JCO.2017.76.9901 (2018). - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources